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This pilot trial is designed to determine whether PET/CT-guided radiotherapy dose escala-
tion can improve local control while minimizing toxicity for the treatment of locally advanced
nasopharyngeal carcinoma.
Methods
67 patients were randomized into the three treatment arms: conventional chemoradiotherapy
(group A), CT-guided dose escalation chemoradiotherapy (group B) and PET/CT-guided
dose escalation chemoradiotherapy (group C). Radiotherapy was delivered using the simul-
taneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation
treatment arms. Patients received concurrent and adjuvant chemotherapy.
Results
The use of PET/CT significantly changed the treatment volume delineation of the gross
tumor volume. 3-year local progression-free (LPF) survival rates of three groups were
83.3%, 90.9% and 100%, respectively. The 3-year regional progression-free survival
(RPFS) rates were 95.8%, 95.5% and 100%, respectively. The 3-year disease free survival
(DFS) rates were 79.2%, 86.4% and 95.2%, respectively. The 3-year overall survival (OS)
rates were 83.3%, 90.9% and 95.2%, respectively. The 3-year disease-free survival (DFS)
rates were 79.2%, 86.4% and 95.2%, respectively. No patient had grade 4 late toxicity.
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Conclusions
PET/CT-guided dose escalation radiotherapy is well-tolerated and appears to be superior




Nasopharyngeal carcinoma (NPC) differs from other head and neck malignancies in terms of
its epidemiology, pathology, and treatment outcomes [1]. It is endemic in China and is one of
the major public health problems. Concurrent radiotherapy and chemotherapy is the primary
treatment for patients with NPC [2]. Despite such aggressive treatment, many patients with lo-
cally advanced NPC still develop locally recurrent disease [3]. Since local control is directly re-
lated to patient morbidity and mortality in NPC, there is a strong need to identify methods to
further improve treatment outcome for NPC.
One strategy to improve local control is to escalate the dose of radiotherapy. This is because
local control has been shown to be directly related to the radiotherapy dose [4,5]. Several differ-
ent techniques, including brachytherapy [6], stereotactic radiosurgery [7], and dose-painting
intensity modulated radiotherapy (IMRT) [8], have been used to increase radiotherapy dose.
However, due to the large number of critical anatomic structures near the nasopharynx, dose-
escalation in NPC can also lead to increased toxicities [9]. The main challenge for such a treat-
ment is to identify the appropriate tumor volume to receive the high-dose radiotherapy. Con-
ventional dose-escalation is conducted using computed tomography (CT) to identify the gross
tumor volume (GTV). However, recent progress with fluorine-18-fluorode-oxyglucose posi-
tron emission tomography/computed tomography (18F-FDG-PET/CT) in treatment planning
allows more accurate tumor volume delineation [10]. We hypothesize that the use of PET/CT
in treatment planning can improve dose-escalation radiotherapy for NPC, which in turn can
improve therapeutic efficacy while reducing toxicity. Given that there has been no clinical trials
directly comparing conventional chemoradiotherapy to CT-guided dose-escalation chemora-
diotherapy or PET/CT guided dose-escalation chemoradiotherapy in locally advanced NPC,
our study aims to compare the local control, overall survival and toxicities of the three
treatment regimens.
Materials and Methods
Study objectives and eligibility criteria
This study was approved by the Institutional Review Board of Xuzhou Medical School
(S1 Checklist). All procedures were in accordance with the ethical standards of the responsi-
ble committee on human experimentation and with the Helsinki Declaration of 1975, as re-
vised in 2008 (S1 Protocol). As a pilot trial, patients with previously untreated Stages III
and IVA (AJCC 6th Edition) of locally advanced NPC, Karnofsky performance status70,
and good bone marrow, liver and kidney function (white blood cell count  4.0×109/L,
platelets  100×109/L, albumin30 g/L, creatinine100μmol/L) were enrolled on this study
between February 2009 to March 2011. Written informed consent was obtained from each
patient. Patients younger than 18, as well as those with a prior (within 5 years) or
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synchronous malignancy were excluded. Pretreatment evaluation consisted of a history and
physical, dental and laboratory studies. The clinical stage was determined based on all infor-
mation provided by examinations including contrast enhanced CT and magnetic resonance
imaging (MRI) of head and neck, chest radiograph, liver sonography, bone scan, and
18F-FDG-PET. All tumors were histologically confirmed except those of distant metastases.
The primary objective of our study was to compare the local progression-free (LPF) survival
rates of the three treatment regimens. Our secondary objectives were to compare the change in
staging from PET imaging, regional progression-free survival (RFS), disease-free survival
(DFS), overall survival (OS), and acute and late toxicities. When this trial was initiated, our in-
stitution did not register our clinical trials with international registries such as clinicaltrials.
gov. Like other trials during the same enrollment period from our institution, this trial was not
registered with clinicaltrials.gov until enrollment has completed. The infrastructure and sup-
port for trial registration has since been made available and all ongoing and related trials for
this drug/intervention are registered.
Study Design
Patients who met the eligibility criteria were randomized 1:1:1 into the three treatment arms:
conventional chemoradiotherapy (group A), CT-guided dose escalation chemoradiotherapy
(group B) and PET/CT-guided dose escalation chemoradiotherapy (group C). All patients
were given concurrent chemoradiotherapy within two weeks of diagnosis (Fig 1).
For radiotherapy treatments, patients were immobilized in the supine position with a ther-
moplastic mask extending to the shoulders. In groups A and B, GTVs were delineated based on
fusing diagnostic CT images with simulation CT images. For group C, images from a diagnostic
PET/CT are fused to the treatment CT. Areas with standardized uptake value (SUV)2.5 were
used as the GTV [11,12]. Two clinical target volumes (CTVs) were delineated: CTV1 and
CTV2. CTV1 was defined as GTV plus a 5 to 10 mmmargin (2 to 3 mmmargin posteriorly) to
encompass the high-risk sites of microscopic extension (including the parapharyngeal spaces,
posterior third of nasal cavities and maxillary sinuses, pterygoid processes, base of skull, lower
half of sphenoid sinus, anterior half of clivus, and petrous tips), and the level of the lymph
node located (bilateral levels IIa, IIb, III, and Va are routinely covered for all N0 patients,
whereas ipsilateral levels IV, Vb, or supraclavicular fossae were also included for N1 patients).
CTV2 was defined as the CTV1 plus a 5 to 10 mmmargin (2 to 3 mmmargin posteriorly) to en-
compass the low-risk sites of microscopic extension. The planning target volume (PTV) was
defined as the CTV plus 3-mmmargins. Patients in group A received radiotherapy delivered
with the intensity modulated radiotherapy (IMRT) technique. PTV1 received 70 Gy in 2 Gy
per fraction whereas PTV2 received 58 Gy in 2 Gy per fraction in groups A. For groups B and
C, PTV1 received 63 Gy and PTV2 received 54 Gy, all in 1.8 Gy per fraction. In addition, the
GTV received 70 Gy in 2.2 Gy per fraction in group B and the GTV received 77Gy in 2.4 Gy
per fraction in group C. Radiotherapy was delivered using the SMART-IMRT technique in the
dose-escalation treatment arms [13]. Parotid gland dose was limited to a mean dose below
30Gy [14] and the temporal lobes dose was limited to below 55Gy, both without compromising
PTV or GTV coverage. Other dose constraints were used per RTOG 0225 protocol.
Concurrent chemotherapy consisted of cisplatin (20 mg/m2, IV, d1–4) and docetaxel
(75 mg/m2, IV, d1 and d8) administered on the 1st and 4th week of treatment. All patients re-
ceived adjuvant chemotherapy (starting 4 weeks after radiotherapy) of the same dose and drug
regimen that ranged from 2 to 4 cycles.
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Follow-up and statistical analysis
Planned patient assessments included physical examination and fiberoptic nasopharyngoscopy
every 3 months, starting at 4 weeks and ending 3 years post-treatment. A contrast-enhanced
CT or MRI of the head and neck is also obtained at each follow up. After 3 years, the patients
were followed yearly thereafter. Suspected recurrences were histologically proven. To assess for
distant metastasis, CT of the chest and bone scan were obtained every 6 months. During every
follow-up visit, treatment toxicity was assessed. Radiotherapy-related toxicities were graded ac-
cording to the Acute and the Late Radiation Morbidity Scoring Criteria of the Radiation Thera-
py Oncology Group (RTOG) and the European Organization for Research and Treatment of
Fig 1. CONSORT flow diagram of trial.
doi:10.1371/journal.pone.0124018.g001
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Cancer (EORTC). Chemotherapy-related toxicities (except nausea or alopecia) were graded by
the criteria of the WHO.
All events were measured from the date of randomization. The primary endpoint was local
progression-free survival (LPFS), and the secondary endpoints were local control, regional pro-
gression-free survival (RPFS) disease free survival (DFS), overall survival (OS) and radiation
toxicities. LPFS was defined as the time from the beginning of randomization to local progres-
sion of primary tumor area. RPFS was defined as the time from the beginning of randomization
to progression of non-primary tumor within the treatment regions. Overall survival (OS) was
defined as the time from the date of randomization to death or the latest date known to be alive
and compared using Log-Rank test. The patient characteristics between the 3 groups were ana-
lyzed using Fisher’s exact test. The Kaplan-Meier method was used to calculate the rates of
local control, regional control and DFS. Comparison of different treatment groups was per-
formed using log-rank test. Univariate analysis was performed using the log-rank test. The Cox
proportional hazard model was used in the multivariate comparisons, and an estimated hazard
ratio (HR) with a 95% confidence interval (95% CI) was presented. All statistical analyses were
two-sided and a p value of<0.05 was considered statistically significant. All analyses were per-
formed using SPSS version 16.0 software (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
67 eligible patients (43 male, 24 female) with a mean age of 47.5 years (range, 19–68 years)
were enrolled in the study (S1 Table). Characteristics of the patients are outlined in Table 1. All
patients successfully completed treatment within 7 weeks. The mean treatment time was 46
day (range, 44–49 day), 32 to 35 fractions. All patients received the prescription dose of
radiotherapy and concurrent chemotherapy. Among the 63 patients who received adjuvant che-
motherapy, the mean number of cycles received was 3. Of the 4 patients who did not receive ad-
juvant chemotherapy, 2 were from group C and 1 from Groups A and B each. These patients
declined further treatment.
The impact of PET/CT on staging and GTV
In group C, the staging of 3 patients (14.3%) was changed after PET/CT imaging. In one pa-
tient, PET/CT scan revealed tumor invading the orbit and base of skull as well as bilateral level
II lymph nodes, whereas contrast CT did not. The patient’s clinical stage was upstaged from
T3N0M0 to T4N2M0. Another patient was also upstaged from T3N2M0 to T3N3M0 due to
identification of supraclavicular lymph node metastases on PET/CT. In the third patient, PET/
CT identified a second primary tumor, papillary thyroid carcinoma, confirmed by biopsy. The
patient underwent thyroidectomy after chemoradiotherapy for NPC.
To determine the impact of PET/CT on GTV delineation, GTV was drawn using both
PET/CT and planning CT (with contrast). The change in GTV volume was calculated as
(GTVPET—CT-GTVCT)/GTVCT. The absolute value of volume change > 25% was defined as
significant changes. 85.7% (18/21) patients’ GTV were smaller based on PET/CT. The GTV
in 47.6% (10/21) of the patient had significant changes (Table 2). Complete data is included
in S2 Table.
Local control and Survival
The median follow-up was 36 months (range, 20–45 months). All patients were followed ac-
cording to protocol. Group A had 4 patients (16.7%) who died from NPC (survival times were
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10 months, 15 months, 18 months, and 22 months), and 4 patients (16.7%) who developed
local recurrence (all with T4 disease, and with in-field failures in the GTV). 1 patient (4.2%)
had regional recurrence and 5 patients (20.8%) developed distant metastasis (lung metastasis
(1), liver metastasis (1), and bone metastasis (3)). Group B had 2 deaths (9.1%) due to distant
metastasis (survival times were 18 months and 24 months). 2 patients (9.1%) developed local
recurrence (in-field GTV), 1 patient (4.5%) had regional recurrence, and 3 patients (13.6%)
developed distant metastases (lung metastasis (1) and bone metastasis (2)). In group C, 1 pa-
tient (4.8%) died from distant metastasis (survival time was 35 months). All other patients in
group C were free of local and regional recurrence. The 3-year LPF survival rates of three
groups were 83.3%, 90.9% and 100%, respectively. The 3-year regional progression-free sur-
vival (RPFS) rates were 95.8%, 95.5% and 100%, respectively. The 3-year disease-free survival
(DFS) rates were 79.2%, 86.4% and 95.2%, respectively. The 3-year OS rates were 83.3%,
90.9% and 95.2%, respectively. When comparing Group C with group A, 3-year LPF and DFS
were statistically significant (P<0.05) (Fig 2). It is important to note that none of the patients
who did not receive adjuvant chemotherapy had recurrent disease. Complete data is included
in S2 Table.
Table 1. Demographic and Clinical Characteristics of 67 Patients.
Patient characteristics Group A Group B Group C P value*
Patient number 24 22 21
Gender
Male 15 14 14
Female 9 8 7 >0.05
Age (yr)
Range 19~67 20~68 19~64
Mean 47 48 46 >0.05
Clinical stages
III stage 14 13 14
IVa stage 10 9 7 >0.05
T stage
T1 1 1 1
T2 10 9 7
T3 7 5 9
T4 6 6 4 >0.05
N stage
N0 1 1 1
N1 3 4 3
N2 15 14 13
N3 5 3 4 >0.05
Pathologic types
WHO II 5 4 3
WHO III 19 18 18 >0.05
*Chi-square test performed.
Group A: conventional chemoradiotherapy group; Group B: CT-guided dose escalation chemoradiotherapy group; Group C: PET/CT-guided dose
escalation chemoradiotherapy group; WHO: World Health Organization.
doi:10.1371/journal.pone.0124018.t001
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Table 2. The change in GTV volume in Group C patients based on PET/CT.
No GTVC T(cm
3) GTVPET-CT(cm
3) Percent of changes(%)
1 15.28 11.09 -27.42
2 7.43 4.12 -44.55
3 10.62 7.57 -28.72
4 30.15 21.72 -27.96
5 15.26 13.05 -14.48
6 32.41 29.27 -9.69
7 15.37 8.66 -43.66
8 44.13 55.17 25.02
9 4.52 2.77 -38.12
10 18.64 13.14 -29.51
11 19.85 14.68 -26.05
12 49.23 54.94 11.60
13 9.46 5.74 -39.32
14 28.31 22.07 -22.04
15 30.68 26.75 -12.81
16 34.16 28.25 -17.50
17 40.42 34.56 -14.50
18 42.15 47.36 11.00
19 22.38 17.34 -22.39
20 55.64 42.34 -23.80
21 31.75 26.42 -16.79
doi:10.1371/journal.pone.0124018.t002
Fig 2. Kaplan-Meier survival analysis of the treatment groups. (a). The 3-year LPF survival rates of three groups. (b). The 3-year DFS rates of three
groups. Group A: conventional chemoradiotherapy group; Group B: CT-guided dose escalation chemoradiotherapy group; Group C: PET/CT-guided dose
escalation chemoradiotherapy group. The 3-year LPF and DFS were statistically significant between groups A and C (P <0.05).
doi:10.1371/journal.pone.0124018.g002
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Toxicity
Toxicity results are shown in Table 3 (acute) and Table 4 (late). The most common acute toxic-
ity was mucositis, with 52.4% to 54.6% grade 2 toxicity and 28.6% to 31.8% grade 3 toxicity.
Late toxicities were grade 1–2 skin dystrophy, subcutaneous fibrosis, xerostomia, and hearing
loss. There were no grade 4 late toxicities. No temporal lobe necrosis was observed. There was
no significant difference in the acute radiation reactions among three groups.
Table 3. The frequency of acute toxicities for the three groups [No. of patient (%)].
Grade 0 Grade 1 Grade 2 Grade 3 χ2 value P value
Mucositis
Group A 0 (0) 3 (12.5) 13 (54.2) 8 (33.3)
Group B 0 (0) 3 (13.6) 12 (54.6) 7 (31.8)
Group C 0 (0) 4 (19.0) 11 (52.4) 6 (28.6) 0.452 0.978
Nausea/vomiting
Group A 1 (4.2) 10 (41.7) 13 (54.2) 0 (0)
Group B 2 (9.1) 9 (40.9) 11 (50.0) 0 (0)
Group C 2 (9.5) 13 (61.9) 6 (28.6) 0 (0) 3.668 0.453
Bone marrow suppression
Group A 5 (20.8) 9 (37.5) 7 (29.2) 3 (12.5)
Group B 6(27.3) 8 (36.3) 6 (27.3) 2 (9.1)
Group C 4(19.0) 9 (42.9) 7 (33.3) 1 (4.8) 1.386 0.967
Skin desquamation
Group A 4 (16.7) 15 (62.5) 3 (12.5) 2 (8.3)
Group B 3 (13.6) 15 (68.2) 3 (13.6) 1 (4.6)
Group C 4 (19.0) 14 (66.7) 2 (9.5) 1 (4.8) 0.767 0.993
doi:10.1371/journal.pone.0124018.t003
Table 4. The frequency of late toxicities for the three groups [No. of patient (%)].
Group A Group B Group C P value
Xerostomia
0 4(16.7) 4(18.2) 5(23.8) 0.968
1 13(54.2) 11(50.0) 11(52.4)
2 7(29.1) 7(31.8) 5(23.8)
3 0 (0) 0 (0) 0 (0)
Skin fibrosis
0 14(58.3) 13(59.1) 15(71.4) 0.942
1 8(33.3) 7(31.8) 5(23.8)
2 2(8.3) 2(9.1) 1(4.8)
3 0 (0) 0 (0) 0 (0)
Subcutaneous fibrosis
0 3(12.5) 2(9.1) 4(19.0) 0.962
1 13(54.2) 13(59.1) 11(52.4)
2 8(33.3) 7(31.8) 6(28.6)
3 0 (0) 0 (0) 0 (0)
Hearing loss
0 3(12.5) 4(18.2) 5(23.8) 0.932
1 14(58.3) 13(59.1) 11(52.4)
2 7(29.2) 5(22.7) 5(23.8)
3 0 (0) 0 (0) 0 (0)
doi:10.1371/journal.pone.0124018.t004
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Discussion
The treatment of locally advanced NPC remains challenging. Despite the advent of concurrent
chemoradiotherapy and IMRT delivery techniques, patients still develop local recurrence with-
in GTV. Multiple reports [4–8] have shown that local control of NPC is correlated with radio-
therapy dose; therefore, many studies have evaluated radiotherapy dose-escalation in NPC.
However, these dose-escalation studies have been single-arm without comparison to conven-
tional radiotherapy. Moreover, dose-escalation has been associated with significant toxicities.
For example, Bakst RL et al. at Memorial-Sloan Kettering Cancer Center (MSKCC) reported
that there is an increased incidence of in-field brain radiation necrosis with dose-escalation in
their prospective dose-escalation trial for nasopharyngeal carcinoma [9]. One strategy to ac-
complish dose-escalation while minimizing toxicity is to improve the delineation of the tumor
volume that needs high-dose radiotherapy. In general, the GTV (area that needs high dose ra-
diotherapy) in radiotherapy is defined by CT imaging. We hypothesized that we can improve
the gross tumor delineation in nasopharyngeal carcinoma by utilizing PET/CT. This study
aimed to compare conventional radiotherapy to CT-guided dose escalated radiotherapy and
PET/CT-guided dose escalated radiotherapy in a randomized fashion.
There are several methods to dose-escalate GTV in NPC. One of the more effective tech-
niques is the SMART-IMRT technique. It delivers both accelerated radiotherapy and hypofrac-
tionated radiotherapy to the GTV. Such an approach can significantly increase the biologically
effective dose (BED) delivered. For example, the BED to GTV is 87 Gy in group B and 95 Gy in
group C. However, the difference in BED between groups A and B is not significant (84 Gy vs
87 Gy). Compared to A, Group B is a more hypofractionated regimen which can have conse-
quences to normal tissue toxicity. Based on the effective dose-escalation with SMART, we uti-
lized this radiotherapy technique in our trial.
Despite the frequent utilization of PET/CT in radiotherapy in head and neck cancer, no
study has directly compared PET/CT-guided dose-escalation to CT-guided dose-escalation
in NPC. Our study aimed to be the first to directly compare the two techniques. We demon-
strated that 47.6% (10/21) of the patients had significant changes in GTV volume with PET/
CT planning when compared to that of CT-based planning. Our results confirmed that PET/
CT can be helpful in tumor volume determination. Our result is not surprising, as Paulino
et al. has shown that GTV determined using PET/CT can be significantly different from that
of CT-based planning [15].
Our study showed that the 3-year local PFS rates of the three treatment groups were 83.3%,
90.9% and 100%, respectively. The difference of PFS between groups A and C is statistically sig-
nificant, though the differences between groups A and B and B and C are not. The 3-year DFS
rates were 79.2%, 86.4% and 95.2%, respectively. Although distant metastasis was the major
cause of death in patients after treatment, our results suggests that the risk of distant metastasis
was decreased with the increase of local control rates. However, it is important to note the limi-
tation of our study. Our data was generated from a single institution pilot trial and the study
may be under-powered. Our data is hypothesis generating and should be further validated in a
large multi-center randomized trial.
The most common acute toxicities were acute mucositis, incidence rates of grade 2 ranged
from 52.4% to 54.6%, and grade 3 ranged from 28.6% to 31.8%. No grade 4 late toxicities were
noted. There was no significant difference in the acute radiation reactions among three groups.
Late toxicities were grade 1–2 skin dystrophy, subcutaneous fibrosis, xerostomia, and hearing
loss. The results of toxicities were similar to with conventional radiotherapy. We also did not
observe any radiation brain necrosis, even in the CT-guided dose-escalation group. The differ-
ence in brain toxicities between our trial and the MSKCC trial is likely due to the fact that our
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PLOSONE | DOI:10.1371/journal.pone.0124018 April 27, 2015 9 / 11
CT-guided dose-escalation group was treated to a lower BED dose. Our PET/CT-guided dose-
escalation group in general had smaller GTV volumes, which can explain the lack of brain tox-
icity in this group.
Conclusions
PET-CT fusion may have significant impact on staging and radiotherapy treatment delineation
in NPC. PET/CT-guided dose escalation radiotherapy appears to be well-tolerated. The SMAR-
T-IMRT technique to enhance BED of GTV, combined with concurrent chemotherapy, is
completely feasible for local advanced NPC. Although the technical advancements have made
it possible to use PET-CT in the radiotherapy planning process, it needs to be supported by ro-
bust clinical data in future studies.
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